Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics Reports Third Quarter 2017 Financial Results
October 26, 2017 4:02 PM EDT-Third Quarter 2017 Revenues Were $135.3 Million, Including $79.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-FDA Breakthrough Therapy Designation Granted for ADCETRIS in Combination with Chemotherapy for Frontline Advanced Classical Hodgkin Lymphoma; Supplemental Biologics License Application on Track for Submission in the Fourth Quarter of 2017-
-Full Data from ADCETRIS Phase 3 ECHELON-1 Trial Accepted for Presentation at ASH Annual Meeting-
-Pivotal Trial Initiated of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer-
-Conference Call Today at 4:30... More
